Metabolic effects of olanzapine in patients with newly diagnosed psychosis / Emilio Fernández Egea en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 2 (Abril)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 154-159 Título : Metabolic effects of olanzapine in patients with newly diagnosed psychosis Tipo de documento: texto impreso Autores: Emilio Fernández Egea, Autor ; Brian J. Miller, Autor ; Clemente Garcia Rizo, Autor Fecha de publicación: 2022 Artículo en la página: pp. 154-159 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Olanzapina, Psicosis, Diabetes, Antecedentes familiares Resumen: Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics. Link: ./index.php?lvl=notice_display&id=29383 [artículo] Metabolic effects of olanzapine in patients with newly diagnosed psychosis [texto impreso] / Emilio Fernández Egea, Autor ; Brian J. Miller, Autor ; Clemente Garcia Rizo, Autor . - 2022 . - pp. 154-159. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 2 (Abril) . - pp. 154-159 Palabras clave: Olanzapina, Psicosis, Diabetes, Antecedentes familiares Resumen: Antipsychotic medications are associated with an increased risk of diabetes. Previous studies have also found an increased risk of type 2 diabetes mellitus in the relatives of schizophrenia probands. The aim of this study was to explore the metabolic adverse effects of olanzapine in a cohort of patients with newly diagnosed psychosis and minimal or no exposure to antipsychotics. Link: ./index.php?lvl=notice_display&id=29383

---

1 (1 - 1 / 1)